uniQure to Participate in Multiple Conferences in February
February 01 2018 - 7:00AM
uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today
announced that members of company management or principal
investigators will participate in upcoming business, medical and
investor conferences during February.
- Bentley University Innovator’s Business Series,
February 6, 2018 at Bentley University in Waltham,
Massachusetts. o Matthew Kapusta, chief
executive officer of uniQure, will be the keynote speaker for a
presentation entitled, “Delivering on the Promise of Gene Therapy”
on Tuesday, February 6, 2018 at 5:00 p.m. EST.
- SunTrust 4th Annual Orphan Drug Day, February 13, 2018
at the JW Marriott Essex House in New York
City o Company management will be hosting
meetings with institutional investors throughout the day.
- Leerink Partners 7th Annual Global Healthcare
Conference, February 14 – 15, 2018 at the Lotte New York Palace
Hotel in New York City o Mr. Kapusta will be
participating in a Fireside Chat on Wednesday February 14, at 9:00
a.m. EST. The live webcast can be accessed by the link displayed in
the Investor section of the uniQure website. The webcast replay
will be available for at least 72 hours following the live
event.
- 13th Annual Huntington's Disease Therapeutics
Conference, February 26 – March 1, 2018 at the Parker Hotel in Palm
Springs, California o Investigators at the
Centre for Molecular Medicine and Therapeutics & BC Children’s
Hospital Research Institute, University of British Columbia,
Vancouver, Canada, will present novel, preclinical data on
uniQure’s proprietary investigational gene therapy, AMT-130, in
humanized mice models of Huntington’s disease. The presentation is
expected to include data demonstrating non-selective silencing of
mutant HTT and improvements in select behavioral and
neuropathological Huntington’s disease phenotypes.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and cardiovascular
diseases.
uniQure Contacts
For
Investors: |
|
For
Media: |
|
|
|
Maria E.
Cantor |
Eva M.
Mulder |
Tom
Malone |
Direct:
339-970-7536 |
Direct: +31 20 240
6103 |
Direct:
339-970-7558 |
Mobile:
617-680-9452 |
Mobile: +31 6 52 33 15
79 |
Mobile:
339-223-8541 |
m.cantor@uniQure.com |
e.mulder@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024